MET - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
FGR	FGR proto-oncogene, Src family tyrosine kinase	FCGR activation Platelet sensitization by LDL Neutrophil degranulation FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis	Dasatinib Fostamatinib Zanubrutinib
GRB2	growth factor receptor bound protein 2	Interleukin-15 signaling Interleukin-15 signaling STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants	Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
GRB7	growth factor receptor bound protein 7	GRB7 events in ERBB2 signaling Signaling by SCF-KIT Downstream signal transduction Tie2 Signaling RET signaling
INPP5D	inositol polyphosphate-5-phosphatase D	Synthesis of PIPs at the plasma membrane Synthesis of IP3 and IP4 in the cytosol Downstream TCR signaling PECAM1 interactions Interleukin receptor SHC signaling
FES	FES proto-oncogene, tyrosine kinase	Signaling by SCF-KIT Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion CRMPs in Sema3A signaling	Fostamatinib
ITGB4	integrin subunit beta 4	Assembly of collagen fibrils and other multimeric structures Laminin interactions Syndecan interactions Type I hemidesmosome assembly	R1295	Epidermolysis bullosa, junctional, including: Epidermolysis bullosa, junctional, Herlitz type (JEB-H); Epidermolysis bullosa, junctional, non-Herlitz type (JEB-nH); Epidermolysis bullosa, junctional, with pyloric atresia (JEB-PA)
PTPRJ	protein tyrosine phosphatase receptor type J	Phosphorylation of CD3 and TCR zeta chains Neutrophil degranulation Negative regulation of MET activity Negative regulation of FLT3
SHC2	SHC adaptor protein 2	Signalling to RAS Signalling to RAS VEGFA-VEGFR2 Pathway RAF/MAP kinase cascade
SHC3	SHC adaptor protein 3	Signalling to RAS Signalling to RAS RAF/MAP kinase cascade RET signaling
SOCS2	suppressor of cytokine signaling 2	Interleukin-7 signaling Neddylation Negative regulation of FLT3 Growth hormone receptor signaling
STK11	serine/threonine kinase 11	AMPK inhibits chREBP transcriptional activation activity Energy dependent regulation of mTOR by LKB1-AMPK Regulation of TP53 Activity through Phosphorylation FOXO-mediated transcription of cell death genes		Peutz-Jeghers syndrome Pancreatic cancer
TEC	tec protein tyrosine kinase	Signaling by SCF-KIT FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization Interleukin-3, Interleukin-5 and GM-CSF signaling	Fostamatinib Zanubrutinib
ABL2	ABL proto-oncogene 2, non-receptor tyrosine kinase	Role of ABL in ROBO-SLIT signaling Role of ABL in ROBO-SLIT signaling Negative regulation of FLT3	ATP Dasatinib XL228 K-00546 Fostamatinib
CCND2	cyclin D2	Cyclin D associated events in G1 Regulation of RUNX1 Expression and Activity Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)		Testicular cancer
INPPL1	inositol polyphosphate phosphatase like 1	Synthesis of PIPs at the plasma membrane Synthesis of IP3 and IP4 in the cytosol Interleukin receptor SHC signaling
ITK	IL2 inducible T cell kinase	Generation of second messenger molecules FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization	Staurosporine Pazopanib Fostamatinib Zanubrutinib
PLXNB1	plexin B1	G alpha (12/13) signalling events Sema4D mediated inhibition of cell attachment and migration Sema4D induced cell migration and growth-cone collapse
RANBP9	RAN binding protein 9	L1CAM interactions RAF/MAP kinase cascade MET activates RAS signaling
SH2B3	SH2B adaptor protein 3	Regulation of KIT signaling Negative regulation of FLT3 Factors involved in megakaryocyte development and platelet production	Pazopanib	Type I diabetes mellitus
SOCS6	suppressor of cytokine signaling 6	Regulation of KIT signaling Neddylation Negative regulation of FLT3

Search Results for: MET